Department of Radiation Oncology, Peter MacCallum Cancer Centre, A'Beckett Street, East Melbourne 3002, Victoria, Australia.
Eur J Surg Oncol. 2012 Feb;38(2):176-80. doi: 10.1016/j.ejso.2011.11.001. Epub 2011 Dec 9.
Preoperative radiotherapy provides advantages in the management of retroperitoneal sarcoma (RPS). We describe our experience treating a cohort who underwent pre- and post-radiotherapy functional imaging with FDG-PET scan.
Consecutive patients presenting between January 1999 and December 2009 with a diagnosis of either primary or recurrent RPS were identified from the hospital patient record database using ICD codes, and cross-referenced with the completed radiotherapy course database. Those patients suitable for preoperative radiotherapy and surgery who underwent both pre- and post-radiotherapy FDG-PET were included. Exclusions included presence of metastatic disease, age under 18 years and/or paediatric histology, and treatment with palliative intent.
Eleven patients were included, of whom six were male. Median age was 63 years (range, 38-78 years). The majority of patients had Stage T2b, high-grade disease. Ten patients were treated at initial presentation and one at first local recurrence. A malignant diagnosis was confirmed in all patients who underwent CT-guided core biopsy; a diagnosis of sarcoma was reached in 91%. Sensitivity of FDG-PET imaging was 100%. Metabolic partial or complete response did not correlate with change in tumour size, nor pathological response assessment. Pulmonary and hepatic metastatic disease was detected in one patient on post-treatment imaging. All patients in the cohort completed preoperative radiotherapy. There was no grade 3 or 4 toxicity. Sixty-four percent proceeded to radical resection. Complete macroscopic excision was achieved in all cases. There was no perioperative mortality.
Combined therapy with preoperative radiotherapy and surgery has acceptable levels of toxicity. CT-guided core biopsy is an accurate means of confirming a diagnosis of RPS prior to definitive treatment. Utility of PET scan in the management of RPS is evolving and further investigation is warranted.
术前放疗为腹膜后肉瘤(RPS)的治疗提供了优势。我们描述了使用 FDG-PET 扫描对接受术前和术后放疗功能成像的患者进行治疗的经验。
使用 ICD 代码从医院患者记录数据库中确定 1999 年 1 月至 2009 年 12 月期间诊断为原发性或复发性 RPS 的连续患者,并与完成的放疗课程数据库交叉引用。包括适合接受术前放疗和手术且接受术前和术后 FDG-PET 的患者。排除标准包括存在转移性疾病、年龄小于 18 岁和/或儿科组织学和姑息治疗。
共纳入 11 例患者,其中 6 例为男性。中位年龄为 63 岁(范围,38-78 岁)。大多数患者处于 T2b 期,高级别疾病。10 例患者在初次就诊时接受治疗,1 例在首次局部复发时接受治疗。所有接受 CT 引导下核心活检的患者均确诊为恶性肿瘤;91%的患者诊断为肉瘤。FDG-PET 成像的灵敏度为 100%。代谢部分或完全缓解与肿瘤大小变化或病理反应评估无关。1 例患者在治疗后影像学检查中发现肺和肝转移。该队列中的所有患者均完成了术前放疗。没有 3 级或 4 级毒性。64%的患者进行了根治性切除。所有病例均实现了完全的大体切除。无围手术期死亡。
术前放疗和手术联合治疗的毒性可接受。CT 引导下核心活检是在确定性治疗前确认 RPS 诊断的准确方法。PET 扫描在 RPS 治疗中的作用正在发展,需要进一步研究。